ライフサイエンスコーパス: AIDS

1 AIDS is a preventable disease.

2 AIDS-related mortality declined with increasing CD4:CD8

3 rrow Transplant Clinical Trials Network 0803/AIDS Malignancy Consortium 071 trial is a multicenter ph

4 nhibitors are crucial for treatment of HIV-1/AIDS, but their effectiveness is thwarted by rapid emerg

5 ted patients on antiretroviral therapy at 20 AIDS clinics.

6 per year in 1996 to 0.65% per year in 2016, AIDS-related mortality decreased from 1.4% per year in 2

7 rson-years, 1834 of 49865 patients died (249 AIDS-related; 1076 non-AIDS-defining; 509 unknown/unclas

8 cancer overall (SIR 1.69, 95% CI 1.67-1.72), AIDS-defining cancers (Kaposi's sarcoma [498.11, 477.82-

9 International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1074 multicenter cohort

10 International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 studies.

11 lar bone loss in some patients with advanced AIDS, in whom CD8+ T cells may also be depleted.

12 Risk for several cancers was higher after AIDS onset and declined across calendar periods.

13 age, sex, and race within the North American AIDS Cohort Collaboration on Research and Design (NA-ACC

14 diagnosis between PLWH in the North American AIDS Cohort Collaboration on Research and Design and the

15 that predict plasma efavirenz exposure among AIDS Clinical Trials Group study participants in the Uni

16 and mortality world-wide, particularly among AIDS patients.

17 eported that infected animals suffer from an AIDS-like disease in the wild.

18 Among PLWH, having an AIDS-defining event was associated with a younger age at

19 t MAIT cells are systemically depleted in an AIDS virus infection.

20 Two hundred thirty-five patients incurred an AIDS-defining illness or died, and 741 patients left fol

21 to ART, are needed to achieve the goal of an AIDS-free generation.

22 ances viral infectivity, immune evasion, and AIDS progression.

23 n HIV from the Joint UN Programme on HIV and AIDS (UNAIDS) from 1988 to 2013 and from data from WHO o

24 We used 2014 Joint UN Programme on HIV and AIDS estimates of adults (aged >15 years) with HIV and a

25 ressing to significant immunodeficiency, and AIDS-defining clinical endpoints in some animals.

26 rica is on track to reduce HIV incidence and AIDS-related mortality substantially by 2030, saving bot

27 ons similar to those for HIV-1 infection and AIDS progression, as well as a characteristic rapid dise

28 esource for information on HIV infection and AIDS.

29 diated signaling in HIV-host interaction and AIDS pathogenesis.

30 tes of the HIV Prevention Trials Network and AIDS Clinical Trials Group.

31 ed as part of the Zambia-South Africa TB and AIDS Reduction Study (2006-2010).

32 nd morbidity and mortality in transplant and AIDS patients.

33 individuals, including organ transplant and AIDS patients.

34 e to NADCs will likely grow in importance as AIDS mortality declines and PWHIV age.

35 e all PLWH and examines associations between AIDS, CD4 count, and age at cancer diagnosis.

36 o compared median age at cancer diagnosis by AIDS status and CD4 count.

37 We tested SIR differences by AIDS status and over time using Poisson regression.

38 ry lymphoid tissues, are readily infected by AIDS viruses and are a major source of persistent virus

39 ive Incidence Function was used to calculate AIDS-related mortality rate.

40 and CD8 count were prognostic for all-cause, AIDS, and non-AIDS mortality in virologically suppressed

41 HIV-1 infection causes AIDS, infecting millions worldwide.

42 sarcoma-associated herpesvirus (KSHV) causes AIDS-related malignancies, including lymphomas and Kapos

43 zations per 100 person-years for all causes, AIDS-defining illnesses, and non-AIDS-defining infection

44 rences observed in those with prior clinical AIDS.

45 Kaposi's sarcoma (KS) as the most common AIDS-associated malignancy is etiologically caused by KS

46 on-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral the

47 nitiation year, and baseline age, CD4 count, AIDS, duration of ART) all-cause and cause-specific mort

48 nt associations with viral load, CD4 counts, AIDS, cancer, or mortality in both cohorts but was indep

49 nfected sooty mangabeys (SMs) do not develop AIDS despite high levels of viremia.

50 ed having a sexual partner who had developed AIDS.

51 on protected rhesus macaques from developing AIDS and partially from vaginal SIV acquisition.

52 The development of an effective AIDS vaccine has been challenging because of viral genet

53 An effective AIDS vaccine should elicit strong humoral and cellular i

54 e hurdles in the development of an effective AIDS vaccine.

55 but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence of HIV and AIDs-related mor

56 a substantial effect on HIV but will not end AIDS, whereas ETP could end AIDS by 2030, with incidence

57 enabling Africa to reach the goal of ending AIDS as a public health threat.

58 Assembly at the High-Level Meeting on Ending AIDS from being achieved.

59 The estimated AIDS-defining illness and non-AIDS-defining infection ho

60 national Epidemiologic Databases to Evaluate AIDS and the Collaboration of Observational HIV Epidemio

61 rnational Epidemiology Databases to Evaluate AIDS-Southern Africa (IeDEA-SA) collaboration.

62 Fewer AIDS-related deaths and an ageing cohort have resulted i

63 PAFs were 2.6% for AIDS-defining cancers (ADCs, including non-Hodgkin lymph

64 nested within the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment

65 Center for AIDS Research, National Institutes of Health, US Departm

66 ere moderately calibrated in the Centers for AIDS Research Network of Clinical Systems but predicted

67 use observational data from the Centers for AIDS Research Network of Integrated Clinical Systems and

68 immunodeficiency virus in the US Centers for AIDS Research Network of Integrated Clinical Systems mul

69 d MI risk estimation models in 5 Centers for AIDS Research Network of Integrated Clinical Systems sit

70 HIV-CAUSAL Collaboration and The Centers for AIDS Research Network of Integrated Clinical Systems.

71 s therefore the major obstacle to a cure for AIDS.

72 ted to lead to viral eradication--a cure for AIDS.

73 United States President's Emergency Plan for AIDS Relief (PEPFAR) Country Operational Plans, and conf

74 The US President's Emergency Plan for AIDS Relief (PEPFAR) supports aggressive scale-up of ant

75 United States President's Emergency Plan for AIDS Relief (PEPFAR), such maps provide essential inform

76 US President's Emergency Plan for AIDS Relief through the Centers for Disease Control and

77 ent area of a President's Emergency Plan for AIDS Relief-supported HIV clinic.

78 ted by the US President's Emergency Plan for AIDS Relief.

79 ssible strategy for anti-viral treatment for AIDS.

80 level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub

81 350, and 200 in threshold 500) and 1091 had AIDS-defining illnesses or died (267 in threshold 200 st

82 were men, 39% were foreign-born, and 22% had AIDS at diagnosis.

83 yan White human immunodeficiency virus (HIV)/AIDS Program (RW) contributes to health outcomes.

84 5 to 2016 using the following Keywords: HIV, AIDS, pregnancy, reproduction, and decision-making.

85 ain a threat to long-term control of the HIV-AIDS epidemic in low- and middle-income countries (LMICs

86 ll on the most disadvantaged living with HIV-AIDS, and are a major driver for HIV-related deaths.

87 HIV/AIDS programmes should consider point-of-care CRP-based

88 HIV/AIDS remains a major health threat despite significant a

89 HIV/AIDS sentinel hospital had better retention, and substan

90 as associated with a risk of accelerated HIV/AIDS progression compared to higher CD4 count (>/=500) (

91 Understanding the factors affecting HIV/AIDS progression is crucial for developing personalized

92 properties as vaccine candidates against HIV/AIDS, and the viral B19 molecule exerts some control of

93 l component of the global battle against HIV/AIDS.

94 als for Alzheimer's disease, cancer, and HIV/AIDS eradication.

95 ield in medicine has moved as swiftly as HIV/AIDS over the past 35 years.

96 t is in clinical development directed at HIV/AIDS eradication, cancer immunotherapy, and the treatmen

97 d novel replicating poxvirus NYVAC-based HIV/AIDS vaccine candidates expressing clade C HIV-1 antigen

98 t of funding ($2.6 billion), followed by HIV/AIDS ($1080.7 million) and malaria ($1028.9 million), wi

99 er support, eye screening can be done by HIV/AIDS clinicians, allowing early tuberculosis treatment.

100 ese poxvirus vectors could be considered HIV/AIDS vaccine candidates based on their activation of pot

101 importance to find a safe and effective HIV/AIDS vaccine that can induce strong and broad T cell and

102 inst HCMV, other herpesviruses, and even HIV/AIDS.

103 , other communicable diseases (excluding HIV/AIDS and tuberculosis) and maternal, perinatal, and nutr

104 the World Bank, the Global Fund to Fight HIV/AIDS, TB and Malaria, and Gavi, the Vaccine Alliance.

105 An inverse relation was seen for HIV/AIDS and tuberculosis mortality and socioeconomic status

106 c status (household wealth) quintile for HIV/AIDS and tuberculosis, other communicable diseases (excl

107 Adolescent Medicine Trials Network for HIV/AIDS Interventions 113 (Project PrEPare) was a PrEP demo

108 Adolescent Medicine Trials Network for HIV/AIDS Interventions 113 enrolled a diverse sample of adol

109 Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads a

110 and 2009, growth in DAH was highest for HIV/AIDS, malaria, and tuberculosis.

111 12,966 individuals received ART from HIV/AIDS sentinel hospitals and 1,919 from DDFs, with linkag

112 dy and pharmacy databases with mandatory HIV/AIDS surveillance monitoring and case management data.

113 The US National HIV/AIDS Strategy (NHAS) aims for 72% (90% diagnosed times 8

114 he recently updated White House National HIV/AIDS Strategy (NHAS) includes specific progress indicato

115 The program addressed National HIV/AIDS Strategy goals 2 through 4 including steps within e

116 se fragmentations by addressing National HIV/AIDS Strategy goals for people living with HIV.

117 ment 3 protocols addressing key National HIV/AIDS Strategy goals.

118 national program to address the National HIV/AIDS Strategy specifically for youths can improve coordi

119 lation continue to bear a high burden of HIV/AIDS and tuberculosis mortality, despite free antiretrov

120 principal barrier to the eradication of HIV/AIDS is the existence of latent viral reservoirs.

121 /EBPs, is involved in the progression of HIV/AIDS, but the exact role of C/EBPbeta and its upstream f

122 ces in Prevention, Treatment and Cure of HIV/AIDS, Guest Editors Steven Deeks, Sharon Lewin, and Lind

123 ls, which may lead to a complete cure of HIV/AIDS.

124 ssociated with the faster progression of HIV/AIDS.

125 protease inhibitors for the treatment of HIV/AIDS.

126 n scientists' approach to the problem of HIV/AIDS.

127 The Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets require that, by 2020, 90

128 by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United States President's Emergenc

129 The Joint United Nations Programme on HIV/AIDS (UNAIDS) has set a "90-90-90" target to curb the hu

130 014, the Joint United Nations Program on HIV/AIDS (UNAIDS) issued treatment goals for human immunodef

131 et the Joint United Nations Programme on HIV/AIDS (UNAIDS) target of diagnosing 90% of those living w

132 of the Joint United Nations Programme on HIV/AIDS (UNAIDS).

133 ving the Joint United Nations Program on HIV/AIDS 95-95-95 target was estimated to avert 25 million [

134 e of more than 200,000 papers written on HIV/AIDS during the past three decades.

135 Combining data from the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol and

136 (NPHIV) pregnant women in the Pediatric HIV/AIDS Cohort Study Surveillance Monitoring of ART Toxicit

137 y HIV-1-infected youths in the Pediatric HIV/AIDS Cohort Study who achieved VS at different ages.

138 n observational database of 22 qualified HIV/AIDS sentinel hospital-based and two CDC-based drug deli

139 e turn of the century, some claimed that HIV/AIDS was a disease that could not be managed in low-inco

140 IV and cancer registries in the USA (the HIV/AIDS Cancer Match Study).

141 The Brazilian response to the HIV/AIDS epidemic demonstrates capabilities that can be appl

142 ons of the world, and exacerbated by the HIV/AIDS pandemic and emergence of multidrug-resistant strai

143 d unexpected pandemics, ranging from the HIV/AIDS pandemic, which began during the Reagan administrat

144 olling for the economy, proximity to the HIV/AIDS problem correlates with the extent to which scienti

145 As the HIV/AIDS research field explores approaches to eliminate HIV

146 odeficiency viruses that may advance the HIV/AIDS vaccine agenda.

147 g with HIV who accessed services through HIV/AIDS sentinel hospital-based and ART service delivery in

148 r CD4 count at baseline to contribute to HIV/AIDS progression (P = 0.023 and P < 0.001, respectively)

149 trends of different topics as related to HIV/AIDS.

150 ng antiretroviral therapy (ART) from two HIV/AIDS clinics in Uganda.

151 ogrammes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child heal

152 s at facilities funded by the Ryan White HIV/AIDS Program (RWHAP), 12.5% (CI, 11.1% to 13.9%) were va

153 2013-2014, including those at Ryan White HIV/AIDS Program (RWHAP)-funded facilities and in private pr

154 and relied on a safety net of Ryan White HIV/AIDS Program support, local charities, or uncompensated

155 Persons living with HIV/AIDS (PLWHA) are at an increased risk of suicide.

156 cause of death among people living with HIV/AIDS (PLWHA).

157 nts such as CBT-AD to people living with HIV/AIDS and examine the cost-effectiveness of such approach

158 hospitalization rates among people with HIV/AIDS in New York City.

159 to estimate the factors associated with HIV/AIDS progression.

160 s to assess risk factors associated with HIV/AIDS progression.

161 gnized as a significant comorbidity with HIV/AIDS, and is an etiologic agent for some human cancers.

162 tic infections that affect patients with HIV/AIDS.

163 e the standard of care for patients with HIV/AIDS.

164 vaccine regimen.IMPORTANCE A failed phase II AIDS vaccine trial led to the hypothesis that CD4(+) T-c

165 ppress residual viral replication.IMPORTANCE AIDS virus persistence in individuals under effective dr

166 In AIDS Clinical Trials Group A5202, participants who repor

167 eficiency virus (HIV) intrahost evolution in AIDS pathogenesis has been limited by the need for longi

168 life-threatening opportunistic infection in AIDS patients.

169 , suggesting their pathogenic involvement in AIDS- or non-AIDS-related complications.

170 re patterns in HIV prevalence and incidence, AIDS-related mortality, and tuberculosis notification ra

171 es, and other conditions, possibly including AIDS.

172 phorylated C/EBPbeta (pC/EBPbeta) influences AIDS progression, but it is still not clear about the ex

173 as malaria, tuberculosis, Ebola, influenza, AIDS, and cancer.

174 International AIDS Vaccine Initiative, National Institutes of Health,

175 Opportunistic Infections, the International AIDS Society Conference, and the International Drug Resi

176 The International AIDS Society convened a group of international experts t

177 lines, urinary catheters, diabetes mellitus, AIDS, end-stage renal disease, and cirrhosis), need for

178 al. described the launch of the Multicenter AIDS Cohort Study (MACS), a cohort study of homosexual m

179 HIV-infected men enrolled in the Multicenter AIDS Cohort Study between 1990 and 2010, there were 182

180 dy and 503 men (65% HIV+) in the Multicenter AIDS Cohort Study who underwent repeated B-mode carotid

181 With longitudinal data from the Multicenter AIDS Cohort Study, a long-term prospective cohort study

182 erosis among participants in the Multicenter AIDS Cohort Study.

183 urine leukemia virus into mice causes murine AIDS, a disease characterized by many dysfunctions of im

184 we used data from the South African National AIDS Council to assess current and future costs under di

185 ic, contrasting with previous data for neuro-AIDS patients where immune tissue Envs mediated a range

186 in the SIV-infected macaque models of neuro-AIDS.

187 o were enrolled in the National Neurological AIDS Bank (NNAB) longitudinal study and autopsy cohort.

188 infected or hepatitis C-co-infected, had new AIDS-defining conditions within 30 days of screening, or

189 Predictors of viral suppression include no AIDS diagnosis and later year of transfer (P </= .05).

190 65 patients died (249 AIDS-related; 1076 non-AIDS-defining; 509 unknown/unclassifiable deaths).

191 d 129 cardiovascular events, 119 and 147 non-AIDS malignancies, 162 and 126 Centers for Disease Contr

192 piratory, liver, and renal diseases, and non-AIDS defining cancers because of their high prevalence a

193 were prognostic for all-cause, AIDS, and non-AIDS mortality in virologically suppressed patients with

194 The estimated AIDS-defining illness and non-AIDS-defining infection hospitalization rates were 1.3 a

195 all causes, AIDS-defining illnesses, and non-AIDS-defining infections.

196 events, NLR-NAR cancer, bone events, and non-AIDS-related infections.

197 line and increased hazard rates for both non-AIDS comorbidities (cardiovascular disease, chronic kidn

198 D8 ratio or CD8 count was prognostic for non-AIDS mortality.

199 n lymphoma, 2.0% of deaths) and 7.1% for non-AIDS-defining cancers (NADCs: lung cancer, 2.3%; liver c

200 he proportion of HIV patients dying from non-AIDS-related disorders.

201 activator receptor (suPAR) and incident non-AIDS comorbidity and all-cause mortality in a well-treat

202 excess adiposity are critical drivers of non-AIDS events in this population.

203 Liver disease is a major cause of non-AIDS-related deaths, and as a result of longer survival,

204 their pathogenic involvement in AIDS- or non-AIDS-related complications.

205 (SMR 5.7, 95% CI 5.5-5.8), particularly non-AIDS infections (10.8, 9.8-12.0) and liver disease (3.7,

206 defining illnesses were relatively rare, non-AIDS-defining infection hospitalizations were more commo

207 ture, cardiovascular disease, and recent non-AIDS cancer (last 12 months) were associated with fractu

208 Serious non-AIDS events cause substantial disease and death despite

209 h of hospitalizations were attributed to non-AIDS-defining infections, whereas AIDS-defining illness

210 une activation have been associated with non-AIDS comorbidity and mortality in human immunodeficiency

211 coccal meningitis was responsible for 15% of AIDS-related deaths (95% CI 10-19).

212 tment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450

213 ognitive disorders (HAND), with about 30% of AIDS patients suffering severe HIV-associated dementias

214 baseline testing for the causative agent of AIDS, the human immunodeficiency virus (HIV).

215 Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-lab

216 stimated hazard ratios (HRs) of death and of AIDS-defining illness or death, risk ratios of virologic

217 y after HIV-1 was discovered as the cause of AIDS, the search for epitopes recognized by neutralizing

218 tudinal Study of the Ocular Complications of AIDS (LSOCA) underwent 5- and 10-year follow-up retinal

219 d the structure of HIV protease in design of AIDS antivirals.

220 y mechanism that leads to the development of AIDS.

221 lays an important role in the development of AIDS.

222 cation and for preventing the development of AIDS.

223 loss ultimately leads to the development of AIDS.

224 flect a combination of historical effects of AIDS, as well as the more general influence of systemic

225 iversification process limit the efficacy of AIDS vaccines.

226 to better understand the natural history of AIDS and its determinants.

227 Patients with a history of AIDS were significantly more likely than uninfected pati

228 tes used in nonhuman primate (NHP) models of AIDS were originally derived from infected macaques duri

229 ol and Prevention to estimate 4-year risk of AIDS and all-cause mortality among 415 patients starting

230 atients who are healthy and have low risk of AIDS-related outcomes should be included absent specific

231 f Kaposi's sarcoma, the most common tumor of AIDS patients.

232 At the second EMBO Workshop on AIDS-Related Mycoses, clinicians and scientists from aro

233 state HIV registration, HIV report date (or AIDS diagnosis, if this was earlier), start of cancer re

234 Corresponding estimates for death or AIDS-defining illness were 1.08 (0.95-1.22) for threshol

235 th human immunodeficiency virus infection or AIDS (P = 0.60).

236 variables for adjustment were age, sex, past AIDS, HIV transmission category, nadir CD4(+) T-cell cou

237 D Using the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-Pediatric model, we simulated

238 rquartile range 16.5,18.1], 27% had previous AIDS diagnosis, CD4 was 444 cells/mm3 [280, 643], 76% we

239 ior osteonecrosis, prior fracture, and prior AIDS.

240 ocking HIV replication and markedly reducing AIDS morbidity and mortality.

241 a sanctuary and a reservoir for replicating AIDS viruses.

242 individuals who presented early with severe AIDS encephalopathy.

243 tural host of SIV that do not develop simian AIDS.

244 ssion and contributes to defining subsequent AIDS pathogenesis.

245 The acquired immune deficiency syndrome (AIDS) epidemic was first recognized in 1981, and it quic

246 IV) and acquired immune deficiency syndrome (AIDS).

247 ated non-acquired immunodeficiency syndrome (AIDS)-related (NLR-NAR) events and mortality in a cohort

248 nts with acquired immunodeficiency syndrome (AIDS).

249 tribute to the design of population-targeted AIDS vaccines by effectively capturing the diversity of

250 Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergr

251 In the last few decades, the AIDS pandemic and the significant advances in the medica

252 anization (WHO), has committed to ending the AIDS epidemic and to ensuring that 90% of people living

253 cide efficacy in the CAPRISA (Centre for the AIDS Program of Research in South Africa) 004 trial.

254 Anal SCC tumor specimens derived from the AIDS and Cancer Specimen Resource (National Cancer Insti

255 The study included participants in the AIDS Clinical Trials Group Longitudinal Linked Randomize

256 /or direct medication assistance through the AIDS Drug Assistance Program (ADAP).

257 HIV-infected participants within the AIDS Clinical Trials Group A5322 HAILO study self-report

258 ective virus-specific CD8 T cells into these AIDS virus sanctuaries and potentially suppress residual

259 Of these, AIDS patients are particularly vulnerable to infection b

260 hs (2791 [58%] of 4808) were attributable to AIDS-defining illnesses.

261 c, and help to achieve the goal of an end to AIDS.

262 f progression of HIV infected individuals to AIDS is known to vary with the genotype of the host, and

263 asis and lymphoid tissue damage that lead to AIDS in HIV-1 and SIVmac infections.

264 ficiency virus (SIV) that do not progress to AIDS when infected with their species-specific viruses.

265 Natural hosts of SIV do not progress to AIDS, in stark contrast to pathogenic human immunodefici

266 ween plasma sCD163 levels and progression to AIDS and all-cause mortality among individuals infected

267 contributes to the more rapid progression to AIDS in infants.

268 e basis of more rapid disease progression to AIDS in infants.IMPORTANCE HIV infection progresses much

269 tive for the onset of disease progression to AIDS in SIV-infected adult macaques.

270 , and it remained high during progression to AIDS.

271 redictive of terminal disease progression to AIDS.

272 e facilitated the accelerated progression to AIDS.

273 oad set point and the rate of progression to AIDS.

274 to associate with accelerated progression to AIDS.

275 s infected with SIV progress more quickly to AIDS than do adults.

276 her viral loads and progress more rapidly to AIDS than infected adults.

277 oimaging from the Comorbidity in Relation to AIDS (COBRA) cohort.

278 5 years, from the Comorbidity in Relation to AIDS cohort, using multimodal neuroimaging and cerebrosp

279 gies have successfully prolonged the time to AIDS onset in HIV-1-infected individuals, a functional c

280 tual development of antiviral drugs to treat AIDS.

281 bility of free treatment and care in the UK, AIDS continues to account for the majority of deaths in

282 uals, typically human immunodeficiency virus/AIDS patients from developing countries.

283 Patients with human immunodeficiency virus/AIDS-associated cryptococcal meningitis (CM) frequently

284 ted to non-AIDS-defining infections, whereas AIDS-defining illness diagnoses were infrequent (3.6% of

285 While AIDS-defining illnesses were relatively rare, non-AIDS-d

286 leading cause of cancers in individuals with AIDS.

287 r >/= 60 years (0.32% to 0.33%) and MSM with AIDS age 30 to 44, 45 to 59, or >/= 60 years (0.29% to 0

288 ning existing CMV retinitis in patients with AIDS after initiating combination antiretroviral therapy

289 Outcome of patients with AIDS continued to improve during a time of widespread av

290 Patients with AIDS have a 1.75-fold increased race- and sex-adjusted i

291 Characteristics of patients with AIDS were compared with ICU patients without AIDS, match

292 Additionally, patients with AIDS were more likely than HIV-uninfected patients to be

293 in reason for ICU admission in patients with AIDS, but their prevalence is declining.

294 ased with age, and was higher in people with AIDS than in those without AIDS (ie, HIV only; adjusted

295 ot diagnosed at a younger age in people with AIDS, with the exception of anal and lung cancers.

296 y in MSM, older individuals, and people with AIDS.

297 Among persons with AIDS who experience immune recovery, there was neither a

298 AIDS were compared with ICU patients without AIDS, matched for age, sex, admission type, and admissio

299 ching levels similar to ICU patients without AIDS.

300 er in people with AIDS than in those without AIDS (ie, HIV only; adjusted incidence rate ratio, 3.82;